دورية أكاديمية
أعرض في EDS

Evaluation and management of febrile neutropenia in patients with cancer.

التفاصيل البيبلوغرافية
العنوان: Evaluation and management of febrile neutropenia in patients with cancer.
المؤلفون: Cossey J; Jason Cossey is an assistant professor and director of didactic education in the PA program at High Point (N.C.) University, and practices in pulmonary and critical care medicine at Novant Health in Charlotte, N.C. Mary Claire B. Cote is a hospitalist at Indiana University Health in Lafayette, Ind. The authors have disclosed no potential conflicts of interest, financial or otherwise., Cote MCB
المصدر: JAAPA : official journal of the American Academy of Physician Assistants [JAAPA] 2024 Aug 01; Vol. 37 (8), pp. 16-20. Date of Electronic Publication: 2024 Jul 25.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Wolters Kluwer Country of Publication: United States NLM ID: 9513102 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1547-1896 (Print) Linking ISSN: 08937400 NLM ISO Abbreviation: JAAPA Subsets: MEDLINE
أسماء مطبوعة: Publication: [Philadelphia, PA] : Wolters Kluwer
Original Publication: Montvale, NJ : Medical Economics,
مواضيع طبية MeSH: Neoplasms*/complications , Febrile Neutropenia*/diagnosis , Febrile Neutropenia*/etiology , Febrile Neutropenia*/therapy , Anti-Bacterial Agents*/therapeutic use , Anti-Bacterial Agents*/administration & dosage, Humans ; Practice Guidelines as Topic ; Risk Assessment ; Fever/etiology ; Fever/therapy
مستخلص: Abstract: Febrile neutropenia is a common oncologic emergency that increases the risk for serious infection. This article reviews a joint American Society of Clinical Oncology and Infectious Diseases Society of America guideline for the evaluation and management of patients with cancer who present with fever and neutropenia. Knowledge and use of available risk assessment tools may reduce unnecessary hospitalizations, decrease inappropriate antibiotic use, and improve patient outcomes.
(Copyright © 2024 American Academy of Physician Associates.)
References: American Cancer Society. Cancer facts & figures 2024. www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2024/2024-cancer-facts-and-figures-acs.pdf . Accessed May 9, 2024.
Gould Rothberg BE, Quest TE, Yeung S-CJ, et al. Oncologic emergencies and urgencies: a comprehensive review. CA Cancer J Clin . 2022;72(6):570–593.
Seltzer JA, Frankfurt O, Kyriacou DN. Association of an emergency department febrile neutropenia intervention protocol with time to initial antibiotic treatment. Acad Emerg Med . 2022;29(1):73–82.
Zimmer AJ, Freifeld AG. Optimal management of neutropenic fever in patients with cancer. J Oncol Pract . 2019;15(1):19–24.
Stephens RS. Neutropenic fever in the intensive care unit. In: Nates JL, Price KJ, eds. Oncologic Critical Care . Springer International Publishing; 2020:1297–1311.
Barré S, McElwee J, Calhoun C, et al. Review of hematological and oncological emergencies. Adv Emerg Nurs J . 2022;44(2):84–102.
Pettit N, Boadu D, Bischof JJ. Emergency department management of chemotherapy related febrile neutropenia: an opportunity to improve care. Am J Emerg Med . 2021;50:5–9.
Jansma B, Vakkalanka P, Talan DA, et al. Guideline adherence for the management of emergency department patients with febrile neutropenia and no infection source: is there room for improvement. J Oncol Pharm Pract . 2020;26(6):1382–1389.
Liu R, Gitman MR, Morris AM, So M. Going local: evaluating guideline adherence and appropriateness of antibiotic prescribing in patients with febrile neutropenia at an academic teaching hospital. Antimicrob Steward Healthc Epidemiol . 2023;3(1):e3.
Ekhtiari Kolour SR, Shahrami B, Kargar M, et al. Adherence to practice guidelines for the management of febrile neutropenia in patients undergoing hematopoietic stem cell transplantation: an observational study in a referral center in Iran. J Oncol Pharm Pract . 2023;29(5):1112–1118.
Jansma B, Vakkalanka P, Talan DA, et al. Guideline adherence for the management of emergency department patients with febrile neutropenia and no infection source: is there room for improvement. J Oncol Pharm Pract . 2020;26(6):1382–1389.
Sereeaphinan C, Kanchanasuwan S, Julamanee J. Mortality-associated clinical risk factors in patients with febrile neutropenia: a retrospective study. IJID Reg . 2021;1:5–11.
Long B, Koyfman A. Oncologic emergencies: the fever with too few neutrophils. J Emerg Med . 2019;57(5):689–700.
Taplitz RA, Kennedy EB, Bow EJ, et al. Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America clinical practice guideline update. J Clin Oncol . 2018;36(14):1443–1453.
Olchowski J, Zimhony-Nissim N, Nesher L, et al. The risk of rectal temperature measurement in neutropenia. Rambam Maimonides Med J . 2023;14(3):e0014.
Coyne CJ, Castillo EM, Shatsky RA, Chan TC. Procalcitonin as a predictive tool for death and ICU admission among febrile neutropenic patients visiting the emergency department. Medicina (Kaunas) . 2022;58(8):985.
Chaftari P, Chaftari A-M, Hachem R, et al. The role of procalcitonin in identifying high-risk cancer patients with febrile neutropenia: a useful alternative to the multinational association for supportive care in cancer score. Cancer Med . 2021;10(23):8475–8482.
de la Court JR, Bruns AHW, Roukens AHE, et al. The Dutch Working Party on Antibiotic Policy (SWAB) recommendations for the diagnosis and management of febrile neutropenia in patients with cancer. Infect Dis Ther . 2022;11(6):2063–2098.
MASCC Risk Index for Febrile Neutropenia. www.mdcalc.com/calc/3913/mascc-risk-index-febrile-neutropenia . Accessed April 22, 2024.
Cooksley T, Font C, Scotte F, et al. Emerging challenges in the evaluation of fever in cancer patients at risk of febrile neutropenia in the era of COVID-19: a MASCC position paper. Support Care Cancer . 2021;29(2):1129–1138.
Hradská K, Popková T, Skořupová M, et al. Management of treatment-related infectious complications in high-risk hemato-oncological patients via telemedicine. Cancer Manag Res . 2022;14:1655–1661.
Zimmer AJ, Stohs E, Meza J, et al. Bloodstream infections in hematologic malignancy patients with fever and neutropenia: are empirical antibiotic therapies in the United States still effective. Open Forum Infect Dis . 2022;9(7):ofac240.
Horita N, Shibata Y, Watanabe H, et al. Comparison of antipseudomonal β-lactams for febrile neutropenia empiric therapy: systematic review and network meta-analysis. Clin Microbiol Infect . 2017;23(10):723–729.
Chaftari A-M, Hachem R, Malek AE, et al. A prospective randomized study comparing ceftolozane/tazobactam to standard of care in the management of neutropenia and fever in patients with hematological malignancies. Open Forum Infect Dis . 2022;9(6):ofac079.
Issani A. An updated narrative review on the management of the most common oncological and hematological emergencies. Dis Mon . 2023;69(2):101355.
Aguilar-Guisado M, Espigado I, Martín-Peña A, et al. Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (How Long study): an open-label, randomised, controlled phase 4 trial. Lancet Haematol . 2017;4(12):e573–e583.
المشرفين على المادة: 0 (Anti-Bacterial Agents)
تواريخ الأحداث: Date Created: 20240709 Date Completed: 20240725 Latest Revision: 20240725
رمز التحديث: 20240726
DOI: 10.1097/01.JAA.0000000000000054
PMID: 38980295
قاعدة البيانات: MEDLINE
الوصف
تدمد:1547-1896
DOI:10.1097/01.JAA.0000000000000054